DDInter233 DDInter1376
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Levonorgestrel
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Brigatinib may lead to a major life threatening interaction when taken with Levonorgestrel
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib